SCHEDULE 13G/A: Sands Capital Management Discloses 4.7% Passive Stake in Ultragenyx Pharmaceutical

Sands Capital Management, LLC and Frank M. Sands have filed an amended Schedule 13G, disclosing a 4.7% beneficial ownership stake in Ultragenyx Pharmaceutical Inc. as of December 31, 2024.

Summary

• Sands Capital Management, LLC (SCM) and Frank M. Sands jointly filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Ultragenyx Pharmaceutical Inc.
• As of December 31, 2024, the reporting persons collectively beneficially own 4,298,003 shares of Ultragenyx Pharmaceutical Inc. Common Stock.
• This aggregate amount represents 4.7% of the outstanding class of securities.
• Sands Capital Management, LLC, an investment adviser, and Frank M. Sands, a control person, hold shared voting power over 2,965,104 shares and shared dispositive power over 4,298,003 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
• The shares are held in accounts for various clients of Sands Capital Management, LLC, including pension plans, endowments, mutual funds, and individuals, with no single client holding more than 5% of the class.

Sentiment

Score: 5

Explanation: The document is a factual regulatory filing disclosing beneficial ownership and does not contain information that inherently suggests a positive or negative sentiment regarding the company's performance or outlook.

Positives

• The disclosure of a significant stake by a reputable institutional investor like Sands Capital Management may be viewed positively by the market, indicating confidence in Ultragenyx Pharmaceutical Inc.

Future Outlook

This document is a beneficial ownership disclosure and does not contain forward-looking statements or guidance from the issuer.

Industry Context

This filing is a routine disclosure of institutional ownership within the biotechnology and pharmaceutical sector. Large institutional holdings are common in this industry, reflecting long-term investment strategies in companies with significant R&D pipelines and market potential.

Comparison to Industry Standards

• Sands Capital Management's 4.7% stake is below the 5% threshold that would typically trigger a new Schedule 13D filing, which is reserved for investors seeking to influence or control the issuer. This indicates a passive investment strategy, consistent with many institutional holdings in the biotech sector.
• The structure of holding shares for various clients, none exceeding 5% individually, is a standard practice for investment advisers managing diversified portfolios.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, potentially influencing investor confidence and perception of the stock's stability.

Key Dates

Keywords

Ultragenyx Pharmaceutical Inc., Sands Capital Management, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, UGEN